title: Antibiotic-resistant acne: getting under the skin.
abstract: Propionibacterium acnes is a key pathogenic factor in the development of acne. Antibiotics are the first choice of treatment for mild-to-moderate, mixed, papular/pustular, and moderate nodular acne, and an alternative choice in severe, nodular/conglobate acne. The emergence of resistance to the currently available antibiotics poses a serious set-back to this algorithm, and the reduced arsenal can diminish efficacy of treatment. This emerging situation should catalyze innovations in dermatology; for example, newer drugs and technologies such as next-generation antibiotics with excellent potency and low propensity to develop resistance, rapid diagnostic platforms to select responders and nonresponders, and delivery technologies that target the bacteria. Such innovations can dramatically expand the arsenal for dermatologists in the management of acne.
authors.affiliation: Vyome Biosciences Pvt Ltd, Delhi, India.
authors.forename: Mau
authors.initials: M
authors.lastname: Sinha
authors.affiliation: Vyome Biosciences Pvt Ltd, Delhi, India.
authors.forename: Suresh
authors.initials: S
authors.lastname: Sadhasivam
authors.affiliation: Vyome Biosciences Pvt Ltd, Delhi, India.
authors.forename: Anamika
authors.initials: A
authors.lastname: Bhattacharyya
authors.affiliation: Vyome Biosciences Pvt Ltd, Delhi, India.
authors.forename: Shilpi
authors.initials: S
authors.lastname: Jain
authors.affiliation: Vyome Biosciences Pvt Ltd, Delhi, India.
authors.forename: Shamik
authors.initials: S
authors.lastname: Ghosh
authors.affiliation: SkinCare Physicians, Chestnut Hill, Massachusetts, USA.
authors.forename: Kenneth A
authors.initials: KA
authors.lastname: Arndt
authors.affiliation: SkinCare Physicians, Chestnut Hill, Massachusetts, USA.
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Dover
authors.affiliation: Department of Medicine, Brigham and Women's Hospital, Cambridge, Massachusetts, USA.|Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Cambridge, Massachusetts, USA. shiladit@mit.edu.
authors.forename: Shiladitya
authors.initials: S
authors.lastname: Sengupta
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D000279:Administration, Cutaneous; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D024881:Drug Resistance, Bacterial; D024901:Drug Resistance, Multiple, Bacterial; D014943:Global Health; D006801:Humans; D008826:Microbial Sensitivity Tests; D015995:Prevalence; D011425:Propionibacterium acnes / Q000187:drug effects; D014481:United States / Q000453:epidemiology
chemical_list: D000900:Anti-Bacterial Agents
keywords: Propionibacterium acnes; acne vulgaris; antibiotic resistance; clindamycin